Search

Your search keyword '"Katayama, Kiyofumi"' showing total 26 results
Start Over Author "Katayama, Kiyofumi"
26 results on '"Katayama, Kiyofumi"'

22. CLINICAL EVALUATION OF CA 15-3 IN BREAST CANCER PATIENTS

Author

SHIMIZU, Satoru, primary, MATSUKAWA, Hiroshi, additional, SASAKI, Hidehiro, additional, KATAYAMA, Kiyofumi, additional, GOTOH, Hisashi, additional, MATSUMOTO, Akihiko, additional, ARITA, Mineo, additional, KOIZUMI, Hiroyoshi, additional, HORIGUCHI, Kazuhiro, additional, JOJIMA, Takao, additional, MATSUMURA, Hiroto, additional, and SUDA, Takashi, additional

Published
1988
Full Text
View/download PDF

24. BLOOD VESSEL INVASION IN BREAST CARCINOMA

Author

NOGUCHI, Yoshikazu, primary, AMANO, Tomishige, additional, MATSUMOTO, Akihiko, additional, SASAKI, Hideyuki, additional, KATAYAMA, Kiyofumi, additional, OKADA, Kenzo, additional, TOMITA, Yoshihiko, additional, ARITA, Eiji, additional, ARITA, Mineo, additional, JINNO, Katsumi, additional, SUMIKAWA, Takayuki, additional, ITO, Takaaki, additional, and KITAMURA, Hajime, additional

Published
1985
Full Text
View/download PDF

25. Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.

Author

Ishikawa T, Shimizu S, Katayama K, Chishima T, Hamaguchi Y, Doi T, Tanabe M, Kasahara A, Yamaguchi N, Narui K, Ohta I, Matsumoto C, Shimizu D, Kito A, Suda T, Inaba M, Asaga T, Momiyama N, Ichikawa Y, Yoshimoto M, Morita S, and Shimada H

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms pathology, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Drug Administration Schedule, Epirubicin administration & dosage, Feasibility Studies, Female, Humans, Japan, Middle Aged, Paclitaxel administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Lymphatic Metastasis
Abstract

Unlabelled: The feasibility and efficacy of adriamycin or epirubicin in combination with cyclophosphamide followed by weekly paclitaxel (AC/EC-weekly PAC) as adjuvant chemotherapy for breast cancer was investigated., Patients and Methods: Node-positive breast cancer was treated with AC/ EC-weekly PAC, namely AC at 60/600 mg/m(2) or EC at 90/600 mg/m(2) x4 at three-week intervals, followed by weekly PAC (80 mg/m(2)) x 12, namely four cycles of single weekly administration for three weeks followed by a one-week rest (3 x 4 PAC) or single weekly administration for 12 consecutive weeks (12 PAC)., Results: One hundred and three of 109 consecutive patients enrolled were analyzed, of whom 96 (93.2%) completed the regimen. Grade 3/4 neutropenia occurred in 52.4% receiving AC/EC, and 10.9% of 55 receiving 12 PAC but only 2.1% of 48 receiving 3 x 4 PAC. Neuropathy disorders occurred in more than half receiving PAC, which did not improve after one-week rest in 3 x 4 PAC., Conclusion: AC/EC-weekly PAC is feasible and without serious complications.

Published
2009

26. [Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report].

Author

Inagaki D, Katayama K, Shiraishi R, Tanabe H, Tani K, Oosawa H, Wada H, and Yasuda S

Subjects
Antineoplastic Combined Chemotherapy Protocols, Camptothecin therapeutic use, Colonic Neoplasms surgery, Drug Combinations, Female, Humans, Irinotecan, Liver Neoplasms secondary, Middle Aged, Ovarian Neoplasms secondary, Ovarian Neoplasms surgery, Tomography, X-Ray Computed, Camptothecin analogs & derivatives, Colonic Neoplasms drug therapy, Colonic Neoplasms pathology, Liver Neoplasms drug therapy, Ovarian Neoplasms drug therapy, Oxonic Acid therapeutic use, Tegafur therapeutic use
Abstract

We report a patient with multiple hepatic metastases and ovarian metastases of transverse colon cancer treated by combination of S-1 and CPT-11. The patient was a 51-year-old woman with cancer of the transverse colon and multiple hepatic metastases. She had undergone surgery. Resection of the transverse colon and left ovary was performed because left ovarian metastases were found during the operation. After the operation, the patient was given chemotherapy with S-1 (120 mg/body on days 1-14) and CPT-11 (150 mg/body on day 1). After completion of 11 courses of chemotherapy, abdominal CT scans revealed that the LDAs of the liver had disappeared, so the patient was judged to have achieved CR. No adverse event was observed. This case suggests that the combination of S-1 and CPT-11 may be an effective regimen for advanced colon cancer with multiple hepatic metastases.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results